Recursion Pharmaceuticals Inc. (RXRX), which recently merged with Exscientia to advance the industrialization of drug discovery, has several key catalysts to watch for in the coming months.
The two companies, which operate in the AI drug discovery space, completed the business combination as recently as Nov.20, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com